Argent BioPharma Expands Clinical Supply of Cannabinoid Therapy in Europe

Argent BioPharma Ltd. (ASX: RGT), a clinical-stage biotech innovator, has officially launched routine hospital supply of its EU-GMP-certified cannabinoid-based active pharmaceutical ingredient (API) for treating drug-resistant epilepsy. The supply began at Slovenia’s largest hospital, the University Medical Centre Ljubljana, following a successful pilot program. Leveraging its flagship product, CannEpil®, and long-standing partnerships with EU-GMP manufacturers like PHCANN International/NYSK Holdings, Argent is now enabling protocol-based prescriptions co-developed under its Epilepsy Program Platform (EPP). This strategic expansion reflects deep collaboration with Slovenian health authorities and reinforces Argent’s regulatory leadership. The initiative underscores the company’s ability to translate pilot success into scalable, regulated hospital programs. Argent’s proprietary delivery platforms and regulatory groundwork also pave the way for broader European and U.S. growth. With a targeted focus on neuroimmune conditions and systemic inflammation, Argent continues to innovate beyond oncology, addressing critical unmet needs in central nervous system disorders

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com